Jeffrey Bronchick: And just again, just when you again recap the regulatory environment, and my guess is nothing happens this year because it’s an election year. But maybe just talk about some of the things that aside from the 75-25 that have come up or not are positive or not, just an overall viewpoint?
Casey Hoyt: I’ll take that one. I mean, the I guess some of the positive things that we’ve seen from a regulatory basis have started on a state-by-state basis. There’s a thing called Step Therapy where some of the payers’ medical policies are asking you to try and fail a lesser device before approving a ventilator and it adds another layer of authorization and burden on frankly the patient more or less than us. I mean for sure our business but more about the patient trying a lesser device and suffocating and then having a document failure before they go into a ventilator. That is wrong and clinically there’s no data that proves that that is a method that we should be embracing. So, we’ve been able to change legislation around Oklahoma, Louisiana.
We’re working on Louisiana and Mississippi and there’s really been no opposition to those efforts because it’s kind of common sense. We’re seeing some of that activity up on the Hill in D.C. as well. AA Home Care is now one of our industry associations that’s behind this movement that’s also spreading this message throughout the country. And I just think that’s an overall positive win for us. I mean we’re dealing with that — we’ve been dealing with that burden for the last two to three years and to get some relief on that would be huge. But other than that, there’s really, I mean, there’s some things that don’t really affect Viemed, but I mean like with diabetes regulations and stuff like that, but really we’re pretty stable from the standpoint of the things that we’re focused on or that would affect our business.
There’s nothing outside of 75-25 that are pressures on reimbursement. And as we’ve communicated, it’s really not that much of a pressure for our business. So again, we couldn’t be more pleased, I guess, with the current state of affairs with on the regulatory front. And frankly, it’s the most stable it’s ever been since I’ve been running the business.
Todd Zehnder: Yes. And I’ll add one thing. I mean, the question we always get is competitive bidding and is it coming back. And while we don’t have an answer to say yes or no, it might. We’re at the point we’re getting close to the point where we can say that we’re confident it won’t be here for 2025. And generally, it gets announced, if you will, about 18 months ahead of time. So, if we don’t hear anything from CMS over the next few months, we’re going to be at a point where we don’t think it will be around for 2026 either. While we don’t — we’re not afraid competitive bidding, we bid in the last round, which got canceled. We just don’t see it coming back in the near term just because it has not been sort of rolled out properly if it’s coming back anytime soon.
Operator: There are no further questions at this time. I’ll hand the floor over to Todd Zehnder for closing comments.
Todd Zehnder: All right. We want to thank everybody for their participation, and please follow-up if you have any additional questions. Thank you.
Operator: This concludes today’s conference call. [Operator Closing Remarks].
